Roche Announces Positive Phase III Results for Fenebrutinib in Multiple Sclerosis

Roche is proceeding with global regulatory submissions for fenebrutinib following positive Phase III results from its FENhance 1 and 2 trials for relapsing multiple sclerosis (RMS). The clinical data demonstrated that the non-covalent BTK inhibitor reduced the annualized relapse rate (ARR) by 51.1% compared to teriflunomide, effectively lowering relapse frequency to once every 17 years. However, the latest updates reveal that seven patient deaths occurred during the studies, a factor that regulators will likely scrutinize alongside the drug's high efficacy. Despite these fatalities, Roche maintains that the drug's ability to suppress brain lesions remains a significant clinical breakthrough. Investors are now weighing the potential for regulatory approval against these safety concerns. This submission marks a critical step for Roche's late-stage pipeline and its long-term valuation on international exchanges.